Mayer E, Kramm T, Dahm M, Moersig W, Eberle B, Düber C, Menzel T, Oelert H
Klinik für Herz-, Thorax- und Gefässchirurgie der Johannes-Gutenberg-Universität Mainz.
Z Kardiol. 1997 Nov;86(11):920-7. doi: 10.1007/s003920050132.
Pulmonary thromboendarterectomy (PTE) is a potentially curative procedure in chronic thromboembolic pulmonary hypertension. From June, 1989, to December, 1994, we performed PTE in 109 consecutive patients. Multiple changes in surgical approach and postoperative management have been implemented since January, 1995. We report the early results of 32 thromboendarterectomies performed from January, 1995, to January, 1997. Thirty-two patients (16 females, 16 males; mean age 55 years) were operated using cardiopulmonary bypass, deep hypothermia and circulatory arrest. Preoperative NYHA functional class was III in 21 and IV in 11 patients. Pulmonary vascular resistance (PVR) and mean pulmonary artery pressure (mPAP) were elevated to 967 +/- 238 dynes.s.cm-5 and 51 +/- 11 mm Hg respectively. The perioperative mortality rate was 9.3% (3 of 32). Twenty-nine survivors were weaned from mechanical ventilation and extubated after a mean of 35 hours (12 to 190 hours). PVR was reduced to 301 +/- 151 dynes.s.cm-5 (p < 0.001) and mPAP was reduced to 28 +/- 10 mm Hg (p < 0.001). Pulmonary thromboendarterectomy is an effective surgical procedure for chronic thromboembolic pulmonary hypertension. By means of modifications in surgical approach and postoperative management, early results can be improved and perioperative mortality can be decreased to less than 10%.
肺动脉血栓内膜剥脱术(PTE)是治疗慢性血栓栓塞性肺动脉高压的一种潜在的根治性手术。从1989年6月至1994年12月,我们连续为109例患者实施了PTE手术。自1995年1月起,我们对手术方法和术后管理进行了多项改进。我们报告了1995年1月至1997年1月期间实施的32例血栓内膜剥脱术的早期结果。32例患者(16例女性,16例男性;平均年龄55岁)在体外循环、深度低温和循环停止下接受手术。术前纽约心脏协会(NYHA)心功能分级为Ⅲ级的有21例,Ⅳ级的有11例。肺血管阻力(PVR)和平均肺动脉压(mPAP)分别升高至967±238达因·秒·厘米⁻⁵和51±11毫米汞柱。围手术期死亡率为9.3%(32例中的3例)。29例幸存者在平均35小时(12至190小时)后停止机械通气并拔除气管插管。PVR降至301±151达因·秒·厘米⁻⁵(p<0.001),mPAP降至28±10毫米汞柱(p<0.001)。肺动脉血栓内膜剥脱术是治疗慢性血栓栓塞性肺动脉高压的一种有效手术方法。通过改进手术方法和术后管理,可以改善早期结果,并将围手术期死亡率降至10%以下。